{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:52:29Z","timestamp":1793332349495,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,28]],"date-time":"2021-02-28T00:00:00Z","timestamp":1614470400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,28]],"date-time":"2021-02-28T00:00:00Z","timestamp":1614470400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"The National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81773175"],"award-info":[{"award-number":["81773175"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"China Postdoctoral Science Foundation in 2018:","award":["2018M630839"],"award-info":[{"award-number":["2018M630839"]}],"id":[{"id":"https:\/\/ror.org\/0426zh255","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The adverse reactions (ADRs) of targeted therapy were closely associated with treatment response, clinical outcome, quality of life (QoL) of patients with cancer. However, few studies presented the correlation between ADRs of targeted therapy and treatment effects among cancer patients. This study was to explore the characteristics of ADRs with targeted therapy and the prognosis of cancer patients based on the clinical data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective secondary data analysis was conducted within an ADR data set including 2703 patients with targeted therapy from three Henan medical centers of China between January 2018 and December 2019. The significance was evaluated with chi-square test between groups with or without ADRs. Univariate and multivariate logistic regression with backward stepwise method were applied to assess the difference of pathological characteristics in patients with cancer. Using the univariate Cox regression method, the actuarial probability of overall survival was performed to compare the clinical outcomes between these two groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 485 patients were enrolled in this study. Of all patients, 61.0% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009296) occurred ADRs including skin damage, fatigue, mucosal damage, hypertension and gastrointestinal discomfort as the top 5 complications during the target therapy. And 62.1% of ADRs were mild to moderate, more than half of the ADRs occurred within one month, 68.6% ADRs lasted more than one month. Older patients (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.022) and patients with lower education level (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.036), more than 2 comorbidities (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.021), longer medication time (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.022), drug combination (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.033) and intravenous administration (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.019) were more likely to have ADRs. Those with ADRs were more likely to stop taking (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.000), change (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.000), adjust (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.000), or not take the medicine on time (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.000). The number of patients with recurrence (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.000) and metastasis (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.006) were statistically significant difference between ADRs and non-ADRs group. And the patients were significantly poor prognosis in ADRs groups compared with non-ADRs group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The high incidence of ADRs would affect the treatment and prognosis of patients with cancer. We should pay more attention to these ADRs and develop effective management strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-021-07946-x","type":"journal-article","created":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T23:34:49Z","timestamp":1614468889000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Adverse reactions of targeted therapy in cancer patients: a retrospective study of hospital medical data in China"],"prefix":"10.1186","volume":"21","author":[{"given":"Ruofei","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon M.","family":"Larcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyue","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2151-7351","authenticated-orcid":false,"given":"Changying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,28]]},"reference":[{"issue":"6","key":"7946_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Lindsey S. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"7946_CR2","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.canlet.2019.10.009","volume":"468","author":"D Yang","year":"2020","unstructured":"Yang D, Yang L, Bai C, Wang X, Powell CA. Epidemiology of lung cancer and lung cancer screening programs in China and the United States. Cancer Lett. 2020;468(5):82\u20137.","journal-title":"Cancer Lett"},{"issue":"5","key":"7946_CR3","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1017\/cjn.2015.59","volume":"42","author":"J Est\u00e8ve","year":"2015","unstructured":"Est\u00e8ve J, Kricker F, Jacques MD. Facts and figures of Cancer in the European Community. Can J Neurol Sci. 2015;42(5):338\u201340.","journal-title":"Can J Neurol Sci"},{"issue":"5","key":"7946_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2017.03.011","volume":"56","author":"TA Barnes","year":"2017","unstructured":"Barnes TA, Amir E, Templeton AJ, Gomez-Garcia S, Navarro B, Seruga B, et al. Efficacy, safety, tolerability and price of newly approved drugs in solid tumors. Cancer Treat Rev. 2017;56(5):1\u20137.","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"7946_CR5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.4103\/apjon.apjon_79_17","volume":"5","author":"GM Wilkes","year":"2018","unstructured":"Wilkes GM. Targeted therapy attacking Cancer with molecular and immunological targeted agents. Asia Pac J Oncol Nurs. 2018;5(2):137\u201355.","journal-title":"Asia Pac J Oncol Nurs"},{"issue":"1","key":"7946_CR6","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12943-018-0804-2","volume":"17","author":"KS Bhullar","year":"2018","unstructured":"Bhullar KS, Lagar\u00f3n NO, Mcgowan EM, Parmar I, Jha A, Hubbard BP, et al. Kinase-targeted cancer therapies: progress, challenges and future directions. Mol Cancer. 2018;17(1):48\u201357.","journal-title":"Mol Cancer"},{"key":"7946_CR7","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1001\/jama.2014.3741","volume":"311","author":"MG Kris","year":"2014","unstructured":"Kris MG, Johnson BE, Berry LD, Kaldal A. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311:2998\u20133006.","journal-title":"JAMA."},{"issue":"14","key":"7946_CR8","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1001\/jama.2019.3241","volume":"321","author":"G Singal","year":"2019","unstructured":"Singal G, Miller PG, Agarwala V, Li G, Kaushik G, Backenroth D, et al. Association of patient characteristics and tumor genomics with clinical outcomes among patients with non\u2013small cell lung Cancer using a Clinicogenomic database. JAMA. 2019;321(14):1391\u2013402.","journal-title":"JAMA."},{"issue":"32","key":"7946_CR9","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.1200\/JCO.2015.61.5997","volume":"33","author":"M Schwaederle","year":"2015","unstructured":"Schwaederle M, Zhao M, Lee JJ, Eggermont AM, Schilsky RL, Mendelsohn J, et al. Impact of precision medicine in diverse cancers: a meta-analysis of phase II clinical trials. J Clin Oncol. 2015;33(32):3817\u201325.","journal-title":"J Clin Oncol"},{"issue":"2","key":"7946_CR10","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s00520-016-3419-4","volume":"25","author":"B Tischer","year":"2017","unstructured":"Tischer B, Huber R, Kraemer M, Lacouture ME. Dermatologic events from EGFR inhibitors: the issue of the missing patient voice. Support Care Cancer. 2017;25(2):651\u201360.","journal-title":"Support Care Cancer"},{"issue":"6","key":"7946_CR11","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1002\/cam4.302","volume":"3","author":"C Porta","year":"2014","unstructured":"Porta C, Levy A, Hawkins R, Castellano D, Bellmunt J, Nathan P, et al. Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries. Cancer Med-Us. 2014;3(6):1517\u201326.","journal-title":"Cancer Med-Us"},{"issue":"1","key":"7946_CR12","first-page":"43","volume":"8","author":"CLELL","year":"2017","unstructured":"CLELL, HASENBANK. Supportive care and Management of Treatment-Emergent Adverse Events with Targeted Therapy in non-small cell lung Cancer. J Adv Pract Oncol. 2017;8(1):43\u201350.","journal-title":"J Adv Pract Oncol"},{"issue":"1","key":"7946_CR13","first-page":"27","volume":"16","author":"Z Bo","year":"2018","unstructured":"Bo Z, Fang C, Deng D, Liang X. Research progress on common adverse events caused by targeted therapy for colorectal cancer. Oncol Lett. 2018;16(1):27\u201333.","journal-title":"Oncol Lett"},{"key":"7946_CR14","first-page":"176","volume":"483\u2013494","author":"ME Cazzaniga","year":"2019","unstructured":"Cazzaniga ME, Danesi R, Girmenia C, Invernizzi P. Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success. Breast Cancer Res Tr. 2019;483\u2013494:176.","journal-title":"Breast Cancer Res Tr"},{"issue":"12","key":"7946_CR15","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1634\/theoncologist.2011-0163","volume":"16","author":"R Dienstmann","year":"2011","unstructured":"Dienstmann R, Bra\u00f1a I, Rodon J, Tabernero J. Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs. Oncologist. 2011;16(12):1729\u201340.","journal-title":"Oncologist."},{"issue":"52","key":"7946_CR16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.cnur.2016.11.005","volume":"1","author":"M Barton-Burke","year":"2017","unstructured":"Barton-Burke M, Ciccolini K, Mekas M, Burke S. Dermatologic reactions to targeted therapy: a focus on epidermal growth factor receptor inhibitors and nursing care. Nurs Clin N Am. 2017;1(52):83\u2013113.","journal-title":"Nurs Clin N Am"},{"issue":"S1","key":"7946_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s40257-018-0384-3","volume":"19","author":"M Lacouture","year":"2018","unstructured":"Lacouture M, Sibaud V. Toxic side effects of targeted therapies and immunotherapies affecting the skin, Oral mucosa, hair, and nails. Am J Clin Dermatol. 2018;19(S1):31\u20139.","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"7946_CR18","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1188\/03.ONF.601-606","volume":"30","author":"S Terri","year":"2003","unstructured":"Armstrong, Terri S. Symptoms Experience: A concept analysis. Oncol Nurs Forum. 2003;30(4):601\u20136.","journal-title":"Oncol Nurs Forum"},{"issue":"1","key":"7946_CR19","first-page":"12","volume":"112","author":"A Freites-Martinez","year":"2020","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the common terminology criteria for adverse events (CTCAE \u2013 version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermo-Sifiliogr\u00e1ficas. 2020;112(1):12\u201322.","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas"},{"issue":"2","key":"7946_CR20","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","volume":"20","author":"DEG Brown","year":"1999","unstructured":"Brown DEG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20(2):109\u201317.","journal-title":"Drug Saf"},{"issue":"3","key":"7946_CR21","first-page":"319","volume":"16","author":"YNK Muro","year":"2016","unstructured":"Muro YNK. Challenges in molecular targeted therapy for gastric cancer considerations for efficacy and safety. Expert Opin Drug Saf. 2016;16(3):319\u201327.","journal-title":"Expert Opin Drug Saf"},{"key":"7946_CR22","doi-asserted-by":"crossref","unstructured":"Deutsch A, Leboeuf NR, Lacouture ME, McLellan BN. Dermatologic Adverse Events of Systemic Anticancer Therapies: Cytotoxic Chemotherapy, Targeted Therapy, and Immunotherapy. Am Soc Clin Oncol Educ Book. 2020 2020-05-01; 40:485\u2013500.","DOI":"10.1200\/EDBK_289911"},{"issue":"52","key":"7946_CR23","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.2147\/CMAR.S163391","volume":"10","author":"CB Chen","year":"2018","unstructured":"Chen CB, Wu MY, Yee NC, Lu CW, Wu J, Pei-Han K, et al. Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies. Cancer Manag Res. 2018;10(52):1259\u201373.","journal-title":"Cancer Manag Res"},{"key":"7946_CR24","unstructured":"Anna J. Lomax, Theresa Nielsen, MCaHaem N, Lydia Visintin. Clinical Nurse Consultant Support: Management of Patients With Melanoma Receiving Immunotherapy and Targeted Therapy. Clin J Oncol Nurs. 2017 2017-08-01; 21(4):E93\u2013E98."},{"issue":"19","key":"7946_CR25","first-page":"1","volume":"22","author":"A Daud","year":"2017","unstructured":"Daud A, Tsai K. Management of Treatment-Related Adverse Events with agents targeting the MAPK pathway in patients with metastatic melanoma. Oncologist. 2017;22(19):1\u201311.","journal-title":"Oncologist."},{"issue":"2","key":"7946_CR26","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s12032-017-1077-0","volume":"35","author":"K Yamamoto","year":"2018","unstructured":"Yamamoto K, Yano I. Genetic polymorphisms associated with adverse reactions of molecular-targeted therapies in renal cell carcinoma. Med Oncol. 2018;35(2):16\u201325.","journal-title":"Med Oncol"},{"issue":"5","key":"7946_CR27","first-page":"357","volume":"11","author":"G Damiani","year":"2018","unstructured":"Damiani G, Manganoni A, Cazzaniga S, Naldi L. Survey of cutaneous adverse reactions to targeted cancer therapies: value of dermatological advice. G Ital Dermatol Venereol. 2018;11(5):357\u201365.","journal-title":"G Ital Dermatol Venereol"},{"issue":"5","key":"7946_CR28","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1097\/NCC.0000000000000521","volume":"41","author":"AL Brunot","year":"2018","unstructured":"Brunot AL, Le Roy F, Le Sourd S, Amel M Sadek, Marielle Duval, Laurence Crouzet, et al. Implementation of a nurse-driven educational program improves management. Cancer Nurs. 2018;41(5):418\u201323.","journal-title":"Cancer Nurs"},{"issue":"13","key":"7946_CR29","first-page":"27","volume":"5","author":"H Staats","year":"2020","unstructured":"Staats H, Cassidy C, Kelso J, Mack S. Targeted molecular therapy in palliative Cancer management. Biomedicine. 2020;5(13):27\u201349.","journal-title":"Biomedicine."},{"issue":"6","key":"7946_CR30","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1097\/jnr.0000000000000339","volume":"27","author":"J Chan","year":"2019","unstructured":"Chan J, Lee Y, Liu C, Shih H. A correlational study of skin toxicity and quality of life in patients with advanced lung Cancer receiving targeted therapy. J Nurs Res. 2019;27(6):e51\u20139.","journal-title":"J Nurs Res"},{"issue":"1","key":"7946_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/15569527.2013.787086","volume":"33","author":"A Patrizi","year":"2014","unstructured":"Patrizi A, Venturi M, Dika E, Maibach H, Tacchetti P, Brandi G. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects. J Toxicol Cutaneous Ocular Toxicol. 2014;33(1):1\u20136.","journal-title":"J Toxicol Cutaneous Ocular Toxicol"},{"issue":"6","key":"7946_CR32","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1111\/bcp.13081","volume":"82","author":"SL Chan","year":"2016","unstructured":"Chan SL, Ang X, Sani LL, Hong YN, Chan A. Prevalence and characteristics of adverse drug reactions at admission to hospital: a prospective observational study. Br J Clin Pharm. 2016;82(6):1636\u201346.","journal-title":"Br J Clin Pharm"},{"issue":"17","key":"7946_CR33","first-page":"286","volume":"133","author":"C Gerv\u00e8s-Pinqui\u00e9","year":"2017","unstructured":"Gerv\u00e8s-Pinqui\u00e9 C, Daumas-Yatim F, Lallou\u00e9 B, Girault A, Ferrua M, Fourcade A, et al. Impacts of a navigation program based on health information technology for patients receiving oral anticancer therapy the CAPRI randomized controlled trial. BMC Health Serv Res. 2017;133(17):286\u201393.","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"7946_CR34","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12885-020-06797-2","volume":"20","author":"K Sano","year":"2020","unstructured":"Sano K, Nakadate K, Hanada K. Minocycline prevents and repairs the skin disorder associated with afatinib, one of the epidermal growth factor receptor-tyrosine kinase inhibitors for non-small cell lung cancer. BMC Cancer. 2020;20(1):279\u201387.","journal-title":"BMC Cancer"},{"issue":"10","key":"7946_CR35","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1111\/jdv.13689","volume":"30","author":"JG Holm","year":"2016","unstructured":"Holm JG, Agner T, Clausen ML, Thomsen SF. Quality of life and disease severity in patients with atopic dermatitis. J Eur Acad Dermatol Venereol. 2016;30(10):1760\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"7946_CR36","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s11096-018-0653-5","volume":"40","author":"G Fornasier","year":"2018","unstructured":"Fornasier G, Taborelli M, Francescon S, Polesel J, Aliberti M, De Paoli P, et al. Targeted therapies and adverse drug reactions in oncology: the role of clinical pharmacist in pharmacovigilance. Int J Clin Pharm-Net. 2018;40(5):795\u2013802.","journal-title":"Int J Clin Pharm-Net"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-07946-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-021-07946-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-07946-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T23:36:24Z","timestamp":1614468984000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-07946-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,28]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["7946"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-07946-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-70708\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,28]]},"assertion":[{"value":"2 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The current study was part of an internal hospital project related to the improvement of the quality of life in cancer patients; the patients\u2019 data we used came from the EMRs, and the data recording is part of the daily work of medical workers, the study was submitted to Ethics Committee of Zhengzhou University, thus, the need for ethics approval was waived by an Institutional Review Board (IRB) of Ethics Committee of Zhengzhou University. We used the data in EMRs so we do not need participants\u2019 informed consent also. Administrative permissions were obtained from directors of oncology departments and information center to access the raw data from the hospital medical records.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No conflict of interest has been declared by the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"206"}}